Thrombophlebitis and cancer. A review.
Thrombophlebitis has been associated with virtually all cancers, especially gastrointestinal, urogenital, and lung neoplasms. Although occurring infrequently in cancer patients, thrombophlebitis may appear before the cancer has become symptomatic and may lead to an earlier diagnosis of cancer. The phlebitic syndrome associated with cancer, although not unique, is distinctive. It is often recurrent and migratory, often involves unusual locations, and is often resistant to anticoagulation therapy. Pulmonary emboli are frequent complications. The pathogenesis of phlebitis in cancer patients is not well understood. Evidence suggests that many cancer patients are hypercoagulable, with abnormalities in platelets, coagulation factors, and the fibrinolytic system. These changes may results from the elaboration of thromboplastin-like substances from the cancer tissue.
D001777:Blood Coagulation; D005342:Fibrinolysis; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000150:complications*; D010190:Pancreatic Neoplasms / Q000150:complications; D011379:Prognosis; D013924:Thrombophlebitis / Q000209:etiology* / Q000503:physiopathology; D013925:Thromboplastin / Q000378:metabolism
D013925:Thromboplastin